Hidradenitis suppurativa with and without draining tunnels: A real‐world study characterizing differences in treatment and disease burden
Patients with moderate-severe HS and draining tunnels experience greater clinical and HR-QoL burden than those without, emphasizing the importance of tunnels in disease impact.
Authors
- Angelo Valerio Marzano (ORCID: https://orcid.org/0000-0002-8160-4169)
- John R Ingram (ORCID: https://orcid.org/0000-0002-5257-1142)
- Sylke Schneider‐Burrus (ORCID: https://orcid.org/0000-0002-9740-6845)
- Alexa B. Kimball (ORCID: https://orcid.org/0000-0001-9405-0479)
- Errol Prospero Prens (ORCID: https://orcid.org/0000-0002-8158-660X)
- Ritesh Jha (ORCID: https://orcid.org/0000-0003-3293-5954)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Aaron Keal (ORCID: https://orcid.org/0009-0004-6368-7476)
- Ana C Hernandez Daly
Institutions
- Beth Israel Deaconess Medical Center (US)
- Boehringer Ingelheim (Germany) (DE)
- Harvard University (US)
- University of Milan (IT)
- Manchester Academic Health Science Centre (GB)
- University Hospital of Wales (GB)
- Erasmus MC (NL)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Northern Health and Social Care Trust (GB)
- Adelphi Group (United Kingdom) (GB)
- Manchester University NHS Foundation Trust (GB)
- NIHR Manchester Biomedical Research Centre (GB)
- Cardiff University (GB)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1111/jdv.20550
- Citations
- 10
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 20.05
Funders
- Boehringer Ingelheim
- Amgen
- Eli Lilly and Company
- Biogen
- Celgene
- Insmed
- LEO Pharma
- Erasmus Universitair Medisch Centrum Rotterdam
- Cilag